Trump Administration Advances Marijuana Rescheduling and Endorses Medical Cannabis Benefits

The Trump administration has taken a significant step in federal cannabis policy, moving forward with the process of marijuana rescheduling after President Donald Trump previously directed the Department of Justice to expedite the effort. Acting Attorney General Todd Blanche confirmed that the administration is now actively working on this change, which comes more than four months after Trump issued an executive order to prioritize the initiative. This development marks a notable shift in federal approaches to cannabis, especially as calls for reform intensify nationwide

President Trump has publicly endorsed the medical use of cannabis, describing it as “the best of all the alternatives” for individuals suffering from serious illnesses. This endorsement from the highest level of government has drawn attention from lawmakers, advocates, and public figures, many of whom see the move as long overdue. However, there are mixed reactions, with some supporters arguing that the rescheduling does not go far enough toward full legalization, while others voice concerns about potential negative consequences

Despite the rescheduling process, Trump administration solicitor general John D. Sauer recently clarified in a Supreme Court filing that this federal action should not affect ongoing legal cases regarding cannabis consumers’ gun rights. According to Sauer, “federal marijuana rescheduling should not change the impact of a case they are considering on cannabis consumers’ gun rights.” This distinction highlights the complex legal landscape that surrounds cannabis reform at the federal level, where overlapping statutes and individual rights remain contentious issues

In Congress, lawmakers are responding with a flurry of legislative activity. Reps. James Comer and Andy Barr of Kentucky introduced amendments to the Farm Bill aimed at delaying the recriminalization of hemp THC products and establishing a framework for continued legal sales, although Barr later withdrew his proposal. Meanwhile, the Senate Veterans’ Affairs Committee has scheduled a hearing on legislation to create a new Department of Veterans Affairs office focused on researching psychedelics and reviewing the scheduling of substances like psilocybin and MDMA. These actions demonstrate how cannabis and related drug policy issues are increasingly shaping federal legislative agendas

At the state and local level, momentum for reform continues. The Alaska Senate Judiciary Committee has added provisions to shield marijuana conviction records in a broader crime bill, and Pennsylvania lawmakers are discussing the fiscal benefits of cannabis legalization. On the advocacy front, the National Cannabis Industry Association is preparing for lobby days in Washington, D.C., reflecting the industry’s push to influence ongoing policy debates. Scientific research also advances, with recent studies highlighting the nutritional and pharmaceutical potential of cannabis and the benefits of integrating psychedelics into palliative care

From the OG Lab newsroom perspective, the Trump administration’s actions signal a pivotal moment for U.S. cannabis policy. The federal push for rescheduling, paired with growing state-level initiatives and active legislative debate, suggests that the landscape for medical and adult-use cannabis is rapidly evolving. Stakeholders across the industry should watch closely as regulatory, legal, and market frameworks adapt to these changes, setting the stage for further reforms and potential opportunities